Sall4 Antibody (Mouse mAb) [D8D9]

CatNo: F5817

    Application: Reactivity:
    • Lane 1: mESC
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    SDS-PAGE の分離ゲルの推奨濃度:5%

    使用情報

    Dilution
    1:1000
    1:100
    1:500
    Application
    WB, IHC, FCM
    Source
    Mouse Monoclonal Antibody
    Reactivity
    Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    112 kDa 140 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Adult mouse testis tissue; Human testis tissue; Juvenile (PND 7 and PND 14) mouse tissue; Adult marmoset testis tissue; HeLa cells; NCCIT cells; mESC cells
    ネガティブコントロール Mouse testis tissue; Human testis tissue; MEF cells; HuES7 cells; MCF7 cells

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 5%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 200 mA, 120 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    Sall4 Antibody (Mouse mAb) [D8D9] detects endogenous levels of total Sall4 protein.
    タンパク質の局在
    細胞質、細胞核
    Uniprot ID
    Q9UJQ4
    Clone
    D8D9
    Synonym(s)
    ZNF797, SALL4, Sal-like protein 4, Zinc finger protein 797, Zinc finger protein SALL4
    Background
    SALL4 is a zinc‑finger transcription factor of the mammalian spalt family that occupies a central position in stem cell transcriptional networks, where it maintains pluripotency and self‑renewal in embryonic stem cells and supports the expansion and fate control of hematopoietic stem and progenitor cells by orchestrating both genetic and epigenetic programs. The protein contains multiple C2H2 zinc‑finger clusters that confer sequence‑specific DNA binding, together with low‑complexity regions that mediate interactions with cofactors such as Nanog, Oct4, Sox2, DNA methyltransferases and epigenetic complexes, allowing SALL4 to act in different stem cell lineages through distinct transcriptional circuitries despite a shared core structural framework. In embryonic stem cells, SALL4 binds a highly conserved distal enhancer of Pou5f1 and activates Oct4 transcription, and reduction of SALL4 levels causes respecification of ES cells toward trophoblast fates with expansion of Cdx2 expression, demonstrating that SALL4 functions as a direct transcriptional activator of Oct4 and is required for maintaining the ESC pluripotent state and early embryonic cell‑fate decisions. Genome‑wide mapping reveals that SALL4 co‑occupies many Nanog and Oct4 sites and regulates large sets of pluripotency genes, while lineage analyses show that SALL4 modulates distinct transcription circuits in embryonic stem cells versus extraembryonic endoderm stem cells, emphasizing its role as a versatile regulator that adapts its target repertoire to specific blastocyst‑derived lineages. In normal hematopoiesis, SALL4 is selectively expressed in primitive CD34+ hematopoietic stem and progenitor cells, is rapidly downregulated as these cells differentiate, and is absent in mature myeloid populations, and forced expression of SALL4A or SALL4B in mouse Lin−/Sca1+/c‑Kit+ LSK cells drives sustained ex vivo proliferation, expansion of functional HSC/HPC pools and enhanced long‑term multilineage repopulation after transplantation, whereas downregulation of endogenous SALL4 reduces LSK proliferation and accelerates differentiation. These stem‑cell‑enhancing activities are accompanied by strong upregulation of key HSC/HPC regulators including HoxB4, Notch1, Bmi‑1, Runx1, Meis1 and NF‑YA, placing SALL4 at the top of a transcriptional hierarchy that boosts self‑renewal and inhibits granulocytic differentiation in myeloid progenitors, and providing a basis for using SALL4 manipulation as a strategy for large‑scale expansion of clinically transplantable stem cells. At the mechanistic level, SALL4 engages epigenetic machinery by binding DNA methyltransferases and associating with their enzymatic activities, increasing global DNA methylation when overexpressed and repressing transcription of targets such as PTEN through recruitment of the NuRD complex, while also activating Bmi‑1 and interacting with Wnt/β‑catenin signaling, generating a SALL4/Wnt/Bmi‑1/PTEN network that integrates chromatin modification with stemness and leukemic transformation. Dysregulated SALL4 expression is reactivated in acute myeloid leukemia and multiple solid tumors, where constitutive SALL4 expression in transgenic mice induces AML and cancer studies show that SALL4 drives proliferation, survival, chemoresistance and maintenance of cancer stem cells through genetic and epigenetic control of downstream oncogenic pathways, making SALL4 a robust cancer biomarker and emerging therapeutic target.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください